Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

3.00
+0.04001.35%
Volume:27.84K
Turnover:86.06K
Market Cap:4.90M
PE:-0.16
High:3.28
Open:3.00
Low:2.93
Close:2.96
52wk High:71.50
52wk Low:2.84
Shares:1.63M
Float Shares:1.22M
Volume Ratio:1.80
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:1.53
PE(LYR):-0.05

Loading ...

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

GlobeNewswire
·
Sep 15

Ernexa Therapeutics CEO Sanjeev Luther Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 14

Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement

Reuters
·
Aug 28

Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation

Reuters
·
Aug 27

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Dow Jones
·
Aug 10

Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview

Reuters
·
Aug 08

Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue

Reuters
·
Aug 07

Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors

Reuters
·
Jul 24

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

GlobeNewswire
·
Jul 24

NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am

Reuters
·
Jul 15

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
Jul 15

Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study

Reuters
·
Jul 15

Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026

THOMSON REUTERS
·
Jul 14

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

GlobeNewswire
·
Jul 14

Ernexa Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 03

Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3

Reuters
·
Jun 27

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

GlobeNewswire
·
Jun 25